2SEVENTY BIO INC's ticker is and the CUSIP is 901384107. A total of 142 filers reported holding 2SEVENTY BIO INC in Q3 2023. The put-call ratio across all filers is 3.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,496,205 | -83.0% | 636,787 | -55.7% | 0.01% | -86.5% |
| Q1 2023 | $14,660,481 | +257.2% | 1,437,302 | +409.6% | 0.04% | +184.6% |
| Q3 2022 | $4,104,000 | -32.0% | 282,058 | -38.3% | 0.01% | -35.0% |
| Q2 2022 | $6,032,000 | -8.1% | 456,934 | +18.7% | 0.02% | -4.8% |
| Q1 2022 | $6,565,000 | – | 384,819 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Newtyn Management, LLC | 1,587,805 | $27,088,000 | 6.49% |
| CHI Advisors LLC | 819,672 | $13,984,000 | 5.95% |
| Madison Avenue Partners, LP | 896,972 | $15,302,342,000 | 2.86% |
| Bain Capital Life Sciences Investors, LLC | 1,408,901 | $24,036,000 | 2.33% |
| EcoR1 Capital, LLC | 3,495,943 | $59,641,000 | 1.87% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $5,118,000 | 1.02% |
| CVI Holdings, LLC | 819,672 | $13,984,000 | 0.92% |
| ARMISTICE CAPITAL, LLC | 2,000,000 | $34,120,000 | 0.66% |
| Altium Capital Management LP | 115,000 | $1,962,000 | 0.66% |
| Casdin Capital, LLC | 614,754 | $10,488,000 | 0.47% |